Rep. Thomas H. Kean, Jr. Sells Johnson & Johnson (NYSE:JNJ) Shares

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on February 19th, the Representative disclosed that they had sold between $15,001 and $50,000 in Johnson & Johnson stock on January 23rd. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/29/2026.
• Sold $15,001 – $50,000 in shares of Stryker (NYSE:SYK) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/23/2026.
• Sold $15,001 – $50,000 in shares of Markel Group (NYSE:MKL) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of General Motors (NYSE:GM) on 1/7/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/26/2025.

Johnson & Johnson Trading Up 1.3%

Shares of JNJ stock opened at $245.53 on Tuesday. The stock has a market capitalization of $591.70 billion, a P/E ratio of 22.22, a P/E/G ratio of 2.35 and a beta of 0.35. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The firm’s 50 day moving average is $221.69 and its 200 day moving average is $199.96. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $246.96.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion for the quarter. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. This represents a 45.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Johnson & Johnson

Several large investors have recently added to or reduced their stakes in JNJ. Clark Asset Management LLC lifted its stake in shares of Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after acquiring an additional 3,025 shares during the period. AustralianSuper Pty Ltd raised its holdings in Johnson & Johnson by 632.0% during the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock worth $16,536,000 after purchasing an additional 77,000 shares during the last quarter. J.W. Cole Advisors Inc. lifted its position in shares of Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock worth $24,278,000 after purchasing an additional 2,769 shares during the period. Guinness Asset Management LTD boosted its stake in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after purchasing an additional 5,994 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its position in shares of Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after buying an additional 94,957 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Company momentum from product mix and recent earnings beat — analysts and commentators point to rising oncology revenues, a MedTech recovery and an earnings surprise as drivers of upside for JNJ. Read More.
• Positive Sentiment: Potential major asset sale — reports say Johnson & Johnson is exploring a sale of its orthopedics unit DePuy Synthes as part of a planned separation; a successful divestiture could unlock cash/value and simplify the company. Read More.
• Positive Sentiment: Clinical data supports Pharma franchise — J&J presented three‑year TREMFYA ulcerative colitis data showing sustained outcomes, which supports longer‑term revenue prospects for immunology assets. Read More.
• Positive Sentiment: Dividend and income appeal remain intact — JNJ’s regular dividend (recently announced/ex‑dividend timing noted in filings) keeps the stock attractive to income and long‑term investors. Read More.
• Neutral Sentiment: Market reports highlight structural tailwinds in vision and cataract devices — sector growth forecasts (phaco systems, femtosecond lasers) could benefit J&J’s device franchises over time but are longer‑term drivers. Read More.
• Neutral Sentiment: Strategic partnerships and analyst noise — a first co‑funding agreement with Blackstone and mixed analyst notes/option activity are being watched but have produced muted immediate market reaction. Read More.
• Negative Sentiment: Bayer lawsuit raises litigation overhang — Bayer sued J&J and Janssen in New York over claims around its Nubeqa prostate‑cancer drug, creating potential legal costs, distraction and uncertainty for Janssen’s oncology positioning. Read More.
• Negative Sentiment: Insider selling disclosed — EVP Timothy Schmid filed a sale of 1,322 shares (additional prior sales also disclosed); routine but may be viewed by some investors as profit‑taking. Read More.

Analysts Set New Price Targets

Several research analysts have issued reports on JNJ shares. Royal Bank Of Canada raised their target price on Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Leerink Partners raised their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. Barclays upped their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a report on Tuesday, December 30th. Rothschild & Co Redburn lifted their price target on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research note on Thursday, February 19th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $232.70.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.